How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
- PMID: 16210286
- PMCID: PMC1246089
- DOI: 10.1136/bmj.331.7520.836
How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?
Abstract
Recent claims that pioglitazone prevents macrovascular events are based on a secondary outcome measure. But ignoring the primary outcome is statistically unsound
Figures
Comment in
-
ASCOT: a tale of two treatment regimens: odds are that it's hype.BMJ. 2005 Oct 29;331(7523):1022-3. doi: 10.1136/bmj.331.7523.1022-b. BMJ. 2005. PMID: 16254307 Free PMC article. No abstract available.
References
-
- Official PROactive results website www.proactive-results.com/index.htm (accessed 15 Sep 2005).
-
- Fisher LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Controlled Clin Trials 1999;20: 16-39. - PubMed
-
- Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 2003;289: 2554-9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical